-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $135

Benzinga·04/25/2025 15:57:25
Listen to the news
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $130 to $135.